Antihyperalgesic effects of intrathecal perospirone in a rat model of neuropathic pain
Antihyperalgesic effects of intrathecal perospirone in a rat model of neuropathic pain
复制标题
DOI:
10.1016/j.pbb.2020.172964
复制
发表时间:
2020-08-01
影响因子:
3.6
通讯作者:
Terada, Tadanori
中科院分区:
文献类型:
--
作者:
Haranishi, Yasunori;Hara, Koji;Terada, Tadanori
The descending serotonergic pathway, from the brainstem to spinal cord, modulates various aspects of pain processing. The spinal 5-hydroxytryptamine (5-HT)(1A) and 5-HT2A receptors play pivotal roles in pain modulation. Perospirone is a novel atypical antipsychotic that serves as a 5-hydroxytryptamine (5-HT)(1A) receptor agonist, a 5-HT2A receptor antagonist, and a dopamine D-2 receptor antagonist. Lithe is known about the effect of perospirone on pain transmission. Here, we explored whether perospirone attenuated neuropathic and inflammatory pain in the spinal cord. A chronic constriction injury to the sciatic nerve was induced in male Sprague-Dawley rats. We evaluated the effects of intrathecal administration of perospirone (10, 20, or 40 mu g) on mechanical and cold hyperalgesia using the electronic von Frey and cold plate tests, respectively. Normal rats were assessed in terms of inflammatory nociception using the formalin WA and for motor coordination employing the rotarod test. To define the mechanism underlying the action of perospirone, the effects of intrathecal pretreatment with the 5-HT1A receptor antagonist WAY-100635, the 5-HT2A/2C receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-aminopropane (DOI), and the dopamine D-2 receptor agonist sumanirole on perospirone action were examined using the electronic von Frey WA and cold plate test. Perospirone dose-dependently alleviated mechanical and cold hyperalgesia, but not inflammatory nociception in the spinal cord, and affected motor coordination. WAY-100635 reversed the antihyperalgesic action of perospirone significantly, but neither DOI nor sumanirole exhibited such an effect. We conclude that perospirone attenuates mechanical and cold hyperalgesia principally via 5-HT1A receptor activation in the spinal cord, and the agent is a promising novel candidate for neuropathic pain relief.